Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benralizumab - AstraZeneca/Kyowa Kirin

Next Previous
Drug Profile

Benralizumab - AstraZeneca/Kyowa Kirin

Alternative Names: Benra; Benralizumab - AstraZeneca/Kyowa Hakko Kirin; Benralizumab - Kyowa-Hakko/AstraZeneca; BIW-8405; BIW-8405-IL-5R; Fasenra; KHK-4563; MEDI-563

Latest Information Update: 05 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioWa
  • Developer AstraZeneca; Kyowa Hakko; Kyowa Kirin; McMaster University; MedImmune; National Jewish Medical and Research Center
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antibronchitics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypereosinophilic syndrome; Eosinophilic oesophagitis; Churg-Strauss syndrome; Eosinophilic gastroenteritis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Preregistration Nasal polyps
  • Phase III Chronic obstructive pulmonary disease; Churg-Strauss syndrome; Hypereosinophilic syndrome
  • Phase II Atopic dermatitis; Rhinosinusitis
  • No development reported Skin disorders
  • Discontinued Bronchiectasis; Bullous pemphigoid; Chronic urticaria; Eosinophilic gastroenteritis; Eosinophilic oesophagitis

Most Recent Events

  • 26 Feb 2024 Efficacy data from the phase III MANDARA trial in Churg-Strauss syndrome released by AstraZeneca
  • 13 Feb 2024 AstraZeneca completes phase-III clinical trials in Eosinophilic gastroenteritis (In adolescents, In adults, In children) in USA, Vietnam, Ukraine, Mexico, Japan, Italy, France, China, Canada, Brazil, Australia (SC) (NCT05251909)
  • 10 Nov 2023 Adverse events and efficacy data from the phase III trial in Churg-Strauss syndrome presented at the American College of Rheumatology Convergence 2023 (ACR-ARP-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top